TrialJournal for immunotherapy of cancer2023

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.

Junsik Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.